Abstract: Surgical literature has been criticized for the lack of high-quality research. The present review examines methodological quality of literature published in head and neck surgical oncology. We focus on landmark studies published on topics of best practice controversy, namely (1) the role of chemotherapy and organ-preservation protocols in the management of head and neck mucosal malignancies; (2) the role of selective neck dissection versus radical neck dissection; and (3) the role of laser microsurgery in the management of larynx cancer. Similar flaws were evident in selected landmark studies with the major issue being multiplicity in the form of multiple outcome analysis, comparison of multiple treatment groups, repeated measures over time, planned interim analyses, and subgroup analyses. The open nonrandomized controlled trial may be a feasible option in head and neck surgical research allowing for standardization, uniformity, consistency, and blinded outcome assessment. V
''Landmark'' papers within the field of head and neck oncology have typically been generated in areas of uncertainty or clinical equipoise related to best practice. In the recent years, the addition of chemotherapy and emergence of organ-preservation protocols created controversy regarding the historically well-defined use of surgery and radiation for the control of mucosal malignancies of the upper aerodigestive tract including oral cavity, pharynx, larynx, and paranasal sinus.
Changes in clinical practice should be rooted in methodologically sound evidence. Surgical research as a whole has been criticized for a lack of randomized controlled trials (RCTs), considered the ''gold standard'' of clinical research, and a reliance on less rigorous study designs such as the case series. 1 In head and neck surgery, the quality of published literature remains largely unexamined. It likely shares common characteristics as other types of surgical literature but is associated with its own set of methodological issues.
The objectives of this work are to review ''landmark'' papers that have had implication for changing clinical practice and examine their methodological strengths and weaknesses. Representative papers from key areas of controversy were identified through polling of the head and neck surgical staff at the University of Toronto. Topics to be examined include (1) the role of chemotherapy and organ-preservation protocols in the management of head and neck mucosal malignancy, (2) the role of selective neck dissection versus radical neck dissection, and (3) the role of laser microsurgery in the management of larynx cancer.
Although the quality of a study can be assessed in many different ways, we focus on key features that can significantly threaten its internal validity, reduce its comparability to other studies, or limit applicability of its results to appropriate patient populations in the clinical setting. Issues to be highlighted include randomization, sample size, control group, study population heterogeneity, and where applicable, the appropriate use of subgroup analysis.
By drawing on methodological lessons learned from landmark studies, we hope to provide suggestions for generating more scientifically rigorous evidence in head and neck surgery. The feasibility and role of the large, simple multicenter trial will be outlined as it relates to appropriate areas of future research within head and neck surgical oncology, where robust results can significantly alter practice and encourage evidencebased medicine.
Organ-Preservation Protocols. Most head and neck tumors typically present with advancedstage locoregional disease (stages III or IV) for which local and regional control with surgery and/ or radiation has been the mainstay treatment. In 1991, the landmark prospective randomized Department of Veteran's Affairs (VA) Laryngeal Cancer Study 2 was published in the New England Journal of Medicine. The use of induction chemotherapy in the treatment of advanced laryngeal cancer with the goal of organ preservation was investigated. A group of 332 patients with previously untreated stage III or IV laryngeal squamous cell carcinoma were randomized to either induction chemotherapy (cisplatin/fluorouracil) followed by definitive radiotherapy for partial or complete responders or to a control arm of total laryngectomy followed by adjuvant radiotherapy. Salvage laryngectomy was planned for all nonresponders or local failures in the neoadjuvant group with an intention-to-treat analysis. After immediate follow-up of 33 months, the estimated 2-year overall survival was 68% for both treatment groups, with no significant differences when patients were grouped according to tumor stage or site. Importantly, the larynx was preserved in 64% of patients overall. There was disparity in the pattern of recurrence with more local recurrences and fewer distant metastases seen in the chemotherapy group. It was suggested that chemotherapy may prevent or at least delay distant metastasis. The major issues surrounding the VA study centered on the ill-defined biology of the neoadjuvant treatment response: did it provide additional cell kill, was it a radiosensitizer, or was it simply a predictor of radiotherapy response? Additional criticism surrounded the lack of comparison with radiotherapy or concomitant chemoradiation arms. As such, the exact role of induction chemotherapy remained uncertain.
In response to these criticisms, a follow-up study was initiated by the Radiation Therapy Oncology Group (RTOG). 3 The RTOG 91-11 trial was a 3-armed multicenter including a neoadjuvant chemotherapy arm, a concomitant chemoradiation arm, and a radiation alone arm. Salvage laryngectomy was planned for nonresponders and local failures. The concomitant chemoradiation group had the highest rate of organ preservation, whereas no significant difference was found between the 3 arms in terms of overall survival. Again, both induction and concurrent chemotherapy significantly reduced distant metastases compared with radiotherapy alone. Understandably, these 2 studies created a frame shift in treatment paradigms and led to emergence of larynx-preservation protocols in the management of advanced laryngeal cancer.
After the publication of the VA study and the RTOG 91-11 trial, there was a rapid proliferation of non-site-specific trials to further investigate organ preservation protocols in the treatment of advanced head and neck squamous cell carcinoma. Over 70 divergent randomized trials compared traditional locoregional treatments of surgery and radiation versus locoregional treatment plus chemotherapy. Unfortunately, this enthusiasm was plagued by small sample sizes and a lack of statistical power to confidently detect even modest effects on survival, leading to mixed results and an obscured clinical picture.
Pignon et al 4 recognized the possible role of meta-analysis in clarifying chemotherapy efficacy. Pooling multiple small studies can potentially compensate for individual reductions of statistical power and increase the strength of inferences made. This Lancet meta-analysis examined randomized trials conducted between 1965 and 1993 on patients with cancer of the oropharynx, oral cavity, larynx, or hypopharynx. Overall, there was a significant benefit in terms of overall survival with the addition of chemotherapy, with a 10% reduction in the hazard ratio of death. This reduction corresponded to an overall survival advantage of 4% both at 2 and 5 years. Planned subgroup analyses revealed that with adjuvant delivery trials, there was in fact no significant benefit, while among concomitant trials, the hazard ratio of death was 0.81 translating into an absolute overall survival benefit at 2 years of 7% and 8% at 5 years. Unfortunately, the meta-analysis was plagued by heterogeneity related to variable tumor subsites, number of chemotherapy agents used, timing of concomitant delivery, inclusion of surgical locoregional interventions, total dose of radiation delivered, and inclusion of variable fractionation schemes (split dose, standard fractionation, hyper-, and accelerated schemes). As such, the appropriateness of data pooling in this case is disputable. In fact, the quantitative benefit of concomitant delivery observed in subgroup analysis came from 14 heterogeneous trials including only 11% of the patients.
As studies established the value of concomitant chemoradiation, its toxicities have also been investigated. The adverse event profile associated with chemotherapy was highlighted by the RTOG 9501/Intergroup study. 5 It was revealed that grade 3/4 mucositis requiring G-tube insertion occurred in 30% of the radiation alone group versus 77% of the combined therapy group. Four patients died as a direct result of treatment in the combined group. This increased, often prohibitive toxicity offset the value of chemoradiation and led to recent interest in monoclonal antibody therapy (eg, cetuximab) for its potential to enhance locoregional control with an improved toxicity profile. A landmark large, multicenter trial conducted by Bonner et al 6 was recently published in the New England Journal of Medicine. Patients with stages III or IV head and neck cancers were randomly assigned to either treatment with high dose radiotherapy alone or high-dose radiotherapy with weekly cetuximab (400 mg/m 2 initial dose followed by 215 mg/m 2 weekly) given for the duration of radiotherapy. The median duration of locoregional control was 24.4 months in the combined arm versus 14.9 months in radiotherapy only. More importantly, there was an impressive median duration of overall survival of 49 months in the combined arm compared with 29 months in the radiation alone arm. There was also no treatment-related mortality and no significant difference with respect to the incidence or severity of toxicity seen between the 2 groups. The authors noted in the discussion that the primary outcome benefit observed compared with the most favorable historical chemoradiation studies. The major criticism that has limited the study's generalizabilty was the absence of the appropriate concomitant chemoradiation group in its design. Another criticism was its association with industry sponsors with multiple authors declaring conflict of interest. A recent meta-analysis by Bhandari et al 7 revealed that industry funding was associated with positive study outcome, when adjusted for study quality and sample size, with an odds ratio of 1.911. This fact may relate to publication bias or, as in this case, the absence of an appropriate standard-of-care treatment comparator. A chemoradiation arm likely would have diminished the clinical outcome differences, thus requiring a larger sample size and a longer follow-up period. Furthermore, even though the attractiveness and clinical application relates to the enhanced toxicity profile, individual patient level quality of life data was not measured, nor was the opportunity cost impact examined with a parallel cost-effectiveness or cost-utility analysis.
Role Selective Neck Dissection Versus Radical
Neck Dissection. Cervical lymph node metastasis has always been a harbinger of poor prognosis, with node-positive status immediately upstaging disease to stage 3 or higher and halving 5-year survival rates. Similar to the mastectomy and breast cancer, management of the neck has evolved from the radical neck dissection pioneered by Crile in 1906 and popularized by Martin in the 1950s. Bocca, Byers, and others [8] [9] [10] [11] [12] [13] [14] suggest that an oncologically safe operation can be achieved by a more selective and functional neck dissection, preserving nonlymphatic structures such as the accessory nerve, the sternocleidomastoid muscle, and the internal jugular vein. They noted that the regional recurrence rates after selective neck dissections were similar to historical controls having undergone radical neck dissection. Unfortunately, the biologic rationale behind these modifications in neck dissection techniques was not fully explained. The regional control rates were used as proof of efficacy for the modified techniques even though cointervention with adjuvant radiation therapy, an important confounding variable, was not accounted for.
In 1990, Shah published the seminal clinicopathologic series reviewing the Memorial SloanKettering Cancer Center experience where 2665 patients underwent radical neck dissection between 1965 and 1985. 10 He excluded 1584 patients from the analysis because they had either a modified neck dissection, suffered from multiple primary tumors, or had received previous treatment such as radiotherapy. Lymph node metastases were confirmed histologically in 82% of 776 therapeutic neck dissections, and micrometastases were identified in 33% of 343 elective radical neck dissections. Using the Memorial Sloan-Kettering Classification Scheme, certain at-risk neck levels were noted to predominate with each respective primary site. Levels I to III were found to be at highest risk for metastasis from cancers of the oral cavity, while levels II to IV were found to be at highest risk for metastasis from the oropharynx, hypopharynx, and larynx. In both the clinically negative and positive necks, the incidence of metastasis to level V was exceedingly small and never occurred in the absence of metastasis to other levels in the neck (excluding cancer of the nasopharynx). By providing data on the pattern of cervical node metastasis, this landmark study demonstrated the necessary oncologic rationale for the selective neck dissection. However, as this study was based on a case series design, it lacked a comparison group and suffered from an obvious lack of denominator. 15 This, in turn, undermined the validity of the inferences made. Despite this, the case series served as a valuable tool for generating hypothesis for further investigation.
Regrettably, there is an overall paucity of clinical trial data examining the exact role of neck dissection in the therapeutic armamentarium. This is related to several factors, including variable primary disease sites with variable metastatic potential, a lack of uniformity and consistency of reporting, variability in operative technique (extent of dissection, number of nodes sampled), and inconsistent pathological analysis (microsection versus simple bisection, immunohistochemical staining). Also, the exact role of neck dissection continues to evolve as emerging cointerventions such as intensity-modulated radiotherapy, altered fractionation schemes (accelerated/hyperfractionation), and CT/positron emission tomography (CT/PET) fusion scans enter into standard clinical practice. Such multiplicity limits trial design feasibility and makes it more difficult for frontline clinicians to adhere to research protocols and achieve the so-called coal-face commitment. 16 Role of Laser Microsurgery in the Management of Laryngeal Cancer. After endoscopic resection of laryngeal cancer was introduced by Lynch in 1915, combined use of the CO 2 laser and the operating microscope was later described by Strong and Jako. 17 Since then, the role of laser surgery, particularly in the treatment of early-stage carcinomas, has been significantly expanded largely due to the work of Steiner et al. 18, 19 Steiner 18 analyzed a subgroup of 240 laryngeal cancer patients of an institutional database of 1200 patients treated by laser microsurgery between 1979 and 1985. Patients were divided into 2 groups according to pathological staging. He noted that among the group with early-stage glottic carcinoma (pTis, pT1, pT2 without nodal, or distant metatasis) the local recurrence rate was 6%, with only 1 patient needing total laryngectomy for salvage. The overall 5-year survival rate was 86.5% with a reported adjusted 5-year survival of 100%. Subjective voice quality was deemed satisfactory in 92% with either slight or no dysphonia as rated by speech language pathologists. The second group included patients with more advanced disease (pT2-pT4, pN0-pN2c) of both the glottis and supraglottis. Those with synchronous second primaries, distant metastasis, or N3 neck disease were excluded. Among this group, the 5-year survival rate was much lower at 59%, and the local recurrence rate was 22% with 6 patients requiring salvage total laryngectomy.
At first glance, the Steiner series could have revolutionized the management of larynx cancer if not for obvious methodological deficiencies affecting both its internal and external validities. This was a single institution experience without a comparator group that has not yet been replicated, raising the specter of overzealous reporting and variability in surgical proficiency and technique. This series likely suffered from selection bias, because without randomization, selection of patients based on known prognostic covariates such as performance status and disease stage is possible. It also makes direct comparison with published radiation series problematic as those with ''poor performance status'' may have been relegated to nonsurgical therapy. Furthermore, this series relied on pathologic staging rather than clinical staging that, although recognized as more accurate, is a form of ascertainment bias that further limits comparison with nonsurgical treatment modalities. Outcome assessment was also plagued by bias as the speech language pathologists were not blinded and comprehensive voice outcome or quality of life assessments were not included. Along with the fact that the adjusted survival estimate ignored mortality related to second primaries, intercurrent disease, regional failure, or distant metastasis, an overestimation of the treatment effect was likely observed. The study also suffered from clinical heterogeneity as the study population had highly variable T and N stages. This was compounded by cointervention with radiation alone, neck dissection, or combination regimes in over one-third of patients, making a clear understanding of who benefits, with what treatment, and when, difficult to discern.
Steiner was certainly pioneering. Indeed, there has only been limited observational comparison studies published on the treatment of early glottic carcinoma with laser microsurgery. [20] [21] [22] [23] To date, no randomized clinical trial evidence exists. 24 Similar issues pervade the widely quoted series on radiation alone, long considered the ''gold standard'' treatment. 25 Trials involving patients with more advanced-stage disease and supraglottic carcinoma are even sparser. The management of early-stage laryngeal carcinoma with laser surgery or radiation remains an area of debate, where true clinical equipoise exists. 26 This would seem to lend itself to a type 3 surgical trial 27 with important outcomes of interest including local control, voice quality, and cost effectiveness.
DISCUSSION

General Issues with Head and Neck Surgical
Oncology Literature. All the selected landmark papers suffer from similar general methodological flaws including multiplicity. 28 Multiple outcome analysis, comparison of multiple treatment groups, repeated measures over time, planned interim analyses, and subgroup analyses are used, creating the statistical ''black-box.'' The concern with multiplicity relates to the increased risk of making inferences based on false-positive results. 28 If many subgroup analyses are performed, it becomes more likely that a statistically significant result will be generated due to chance. In fact, the probability of a false-positive result is given by the formula : 1 2 (1 2 a) G where G is the number of subgroups. 28 In the head and neck literature, it is often difficult to discern whether the adjusted data represents a priori hypothesisdriven analysis or post hoc rationalization. Any subgroup analysis performed therefore should be prespecified, biologically plausible, and any qualitative differences detected must be heavily scrutinized. 29 Finally, these analyses must be recognized as hypothesis generating rather than conclusion forming.
Blinding is a powerful technique to reduce bias, particularly those related to cointerventions and ascertainment of outcome status. Although blinding in surgical trials can be maintained at the database management and statistical analysis level, feasibility at the surgeon or patient level is low. If blinding cannot be strictly maintained, its impact can be reduced by avoiding subjective measures and relying on objective outcome measures.
Within the head and neck literature, there has been variable definition, selection, and reporting of primary outcomes and adverse events. Disparate endpoints examined include overall survival, progression-free survival, disease-free survival, and locoregional control. Such variability makes head-to-head outcome analysis problematic. Complications or adverse events reported can range from major complications (prolonged hospitalization, additional surgical procedures, or those that are deemed life threatening) to so-called minor complications (those that are ''self-limited,'' that can be managed with local wound care or that do not prolong hospitalization). Few randomized control trials are ever big enough to detect rare adverse events, while some small trials may not even be able to detect more common events. Not only are studies likely under-reporting adverse events, if they do, they often use poorly developed survey instruments. Currently, only 3 head and neckspecific multidimensional quality of life instruments (the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-Module [EORTC QLQ-H&N35], the University of Michigan Head and Neck Quality of Life questionnaire and the Head and Neck Cancer Inventory) fulfill guidelines for instrument development and evaluation as outlined by the Medical Outcomes Trust in terms of reliability, validity, and responsiveness to change. 30 
Future Direction
Does It Necessarily Need to be a Randomized Controlled Trial? New operations, unlike new drugs with stable pharmacokinetics and dynamics, continue to evolve with variable skill levels, changing techniques, and inconsistent uniformity in performance of the ''standard'' operation. It is no wonder that surgical trials frequently fail to meet the scientific rigor for randomized control trials. 31 A more appropriate but underused study design is the open multicenter non-RCT and registry. 32 Limiting selection to a well-defined cohort and standardizing the clinical protocol can facilitate forma-tion of a homogeneous study population. This trial structure can discourage performing operations for inappropriate indications, encourage implementation of standardized care, and generate reliable data with inclusion and recording of important covariates. Selection of clinical sites with expertise, and experience is conducive to optimizing the quality of patient care. The multicenter database registry would facilitate comparison of results and attenuate the inherent bias attributed to the surgical skill factor. Even though this scholarly paper has reviewed several methodologically sound ''landmark'' papers, this design would certainly be a generous leap forward for the head and neck surgical literature.
It must be mentioned that even though wellconducted nonrandomized trials or long-term cohort studies historically tend to arrive at similar conclusions as the RCT with regard to value of certain treatment modalities, they inevitably suffer from 1 overwhelming flaw-the lack of control over unknown confounders. Surgical literature is replete with surgical procedures failing to sustain the scientific rigor of the RCT despite being supported by observational studies (eg, external carotid-internal carotid bypass for stroke and endolymphatic shunt surgery for Meniere's disease). 32 What Needs to be Done to Facilitate the Ideal Multicenter Surgical Trial?. The first step in initiating a head and neck surgical trial is to ensure clinical equipoise. As defined by Freedman, clinical equipoise describes a scenario in which the ethical basis for a clinical trial arises from uncertainty within the clinical community as a whole rather than at the individual physician level. 26 Overall, there needs to be a lack of consensus in the expert community as to the superior treatment. 33 The Declaration of Helsinki with its goal of defining acceptable forms of human experimentation is very clear on this and that every patient must be assured the best proven diagnostic and therapeutic methods available. 34 A plenary session should be held for investigator buy in. There should be consensus among investigators that the primary research question is of importance. To maximize clinical applicability, the question should be developed in the PICOT (Population, Invervention, Comparison, Outcome, Timeframe) format. 35 A detailed timeline and study organization would need to be established, including a steering committee. Issues surrounding communication, study protocol, the manual of operations, site visits, data collection and processing, and randomization procedures would require careful consideration. 36 A problem of surgical trials is that there is danger of generating a treatment effect by site interaction based on surgical skill and experience that would invalidate the study results. This potential problem would need to be recognized at the design stage with standardization of management plans, training programs, careful site and surgeon selection, careful recording of all interventions, and monitoring of protocol adherence. The research question would have to involve a surgical procedure that is widely accepted and has been standardized in terms of technique, indications, and equipment. An example of such a procedure is the transoral laser cordectomy for early-stage (stage 1) vocal cord carcinoma.
The technique of central randomization could involve minimization techniques and stratification based on important prognostic variables such as T and N stages and performance status. The treatment by site interactions could be managed with stratification by site, incorporation into a regression model, or by cluster randomization with blocking. However, it is well known that cluster randomized increases the complexity of data management and statistical analysis as the unit of randomization (the site) differs from the level of analysis (the patient). 28 The traditional barrier to surgical trial enrolment relates to patients' unwillingness to submit to the chance-selected intervention. Enhanced acceptability could involve a randomized consent design with prerandomization using Zelen's method. The alternative is a patient-preference trial design where only patients who do not have a preference undergo randomization while the rest are included in an observational cohort study registry. 31 These trial designs have their own set of methodological issues such as the Hawthorne effect, where subjects change their behavior due to study participation. Nonetheless, the open non-RCT is the most feasible option with standardization, uniformity, consistency, and most importantly, a blinded outcome assessment.
Both an unadjusted and adjusted statistical analysis would need to be performed. The relevant prognostic covariates would be identified based on established or suggested correlation with the primary outcome variable and then examined for imbalance with a first-order analysis. These covariates would need to be included in a Cox proportional hazards model. Health-related quality of life and cost effectiveness are becoming increasingly important in assessing the effect of intervention in controlled trials. To this end, secondary outcome data would be collected in parallel, including fixed and variable cost information as well as disease-specific quality of life information.
The final caveat is that it must be made simple, remembering the adage: ''if you make it 10 times bigger, you have to make it 10 times simpler because there is not 10 times the money.'' 31 
